Scott G Filler

US Patent:

8541008, Sep 24, 2013

Filed:

Sep 13, 2002

Appl. No.:

10/245802

Inventors:

Scott G. Filler - Rancho Palos Verdes CA, US
Donald C. Sheppard - Marina Del Rey CA, US
Ashraf S. Ibrahim - Playa Del Rey CA, US
Yue Fu - La Habra CA, US
Bradley J. Spellberg - Ranchos Palos Verdes CA, US

Assignee:

Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

A61K 39/00
A61K 49/00
A61K 38/00
C07K 1/00

US Classification:

4242741, 4241851, 4241841, 424 92, 514 11, 530824, 530350, 530300

Abstract:

A bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

US Patent:

20060083750, Apr 20, 2006

Filed:

May 5, 2005

Appl. No.:

11/123873

Inventors:

John Edwards - Palos Verdes CA, US
Scott Filler - Rancho Palos Verdes CA, US
Donald Sheppard - Montreal, CA
Ashraf Ibrahim - La Mirada CA, US
Yue Fu - Torrance CA, US
Brad Spellberg - Rancho Palos Verdes CA, US
Michael Yeaman - Redondo Beach CA, US

International Classification:

A61K 39/00
C12N 1/18

US Classification:

424185100, 424274100, 435254220

Abstract:

The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing disseminated candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of to a host cell or tissue. The Als protein family member can be derived from a strain selected from the group consisting of and and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p.

US Patent:

20070077256, Apr 5, 2007

Filed:

Jan 6, 2006

Appl. No.:

11/327197

Inventors:

John Edwards - Palos Verdes CA, US
Ashraf Ibrahim - La Mirada CA, US
Brad Spellberg - Rancho Palos Verdes CA, US
Yue Fu - Torrance CA, US
Scott Filler - Rancho Palos Verdes CA, US
Michael Yeaman - Redondo Beach CA, US

International Classification:

A61K 39/02

US Classification:

424190100

Abstract:

The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of to a host cell or tissue. The Als protein family member can be derived from a Candida strain selected from the group consisting of and and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing infections. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

US Patent:

20110059111, Mar 10, 2011

Filed:

Sep 1, 2010

Appl. No.:

12/874126

Inventors:

ASHRAF S. IBRAHIM - IRVINE CA, US
MINGFU LIU - CARSON CA, US
BRAD J. SPELLBERG - RANCHO PALOS VERDES CA, US
SCOTT FILLER - RANCHO PALOS VERDES CA, US
YUE FU - TORRANCE CA, US
JOHN E. EDWARDS - PALOS VERDES ESTATES CA, US

Assignee:

LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER - TORRANCE CA

International Classification:

A61K 39/395
A61P 31/10
A61K 31/713
A61K 39/00

US Classification:

4241721, 514 44 A, 4241841

Abstract:

The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.

US Patent:

20120014995, Jan 19, 2012

Filed:

Jan 10, 2011

Appl. No.:

12/987949

Inventors:

Ashraf Ibrahim - La Mirada CA, US
Brad J. Spellberg - Rancho Palos Verdes CA, US
Yue Fu - Torrance CA, US
Scott G. Filler - Rancho Palos Verdes CA, US
Michael Yeaman - Redondo Beach CA, US

International Classification:

A61K 39/00
A61P 37/06
A61P 31/10

US Classification:

4242741

Abstract:

The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of to a host cell or tissue. The Als protein family member can be derived from a strain selected from the group consisting of and and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing infections. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

US Patent:

20130108642, May 2, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/620563

Inventors:

Ashraf S. Ibrahim - Irvine CA, US
Mingfu Liu - Carson CA, US
Teklegiorgis Ghebremariam - Los Angeles CA, US
Yue Fu - Torrance CA, US
John E. Edwards - Palos Verdes Estates CA, US
Scott Filler - Rancho Palos Verdes CA, US

International Classification:

C07K 14/37
C07K 16/14

US Classification:

4241391, 536 2374, 4353201, 4352523, 4352542, 435325, 435365, 435362, 435367, 435357, 435369, 435353, 435348, 43525421, 43525423, 43525233, 536 245, 536 2432, 536 2433, 530350, 435 693, 5303879, 514 44 A, 435 611, 435 612, 435 731, 4241851

Abstract:

The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.

US Patent:

20140037689, Feb 6, 2014

Filed:

Mar 5, 2013

Appl. No.:

13/785835

Inventors:

Ashraf S. Ibrahim - Irvine CA, US
Brad J. Spellberg - Rancho Palos Verdes CA, US
Yue Fu - Carson CA, US
Scott G. Filler - Rancho Palos Verdes CA, US
Michael R. Yeaman - Redondo Beach CA, US

International Classification:

A61K 39/00

US Classification:

4242741

Abstract:

The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of to a host cell or tissue. The Als protein family member can be derived from a strain selected from the group consisting of and and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing infections.

US Patent:

7067138, Jun 27, 2006

Filed:

Nov 18, 2000

Appl. No.:

09/715876

Inventors:

Scott G. Filler - Rancho Palos Verdes CA, US
Donald C. Sheppard - Montreal, CA
Ashraf S. Ibrahim - La Mirada CA, US
Yue Fu - Torrance CA, US
Bradley J. Spellberg - Ranchos Palos Verdes CA, US

Assignee:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

A61K 39/00
A61K 38/00
C07K 1/00
C07K 2/00

US Classification:

4242741, 4241841, 4241851, 530350, 530300, 530824, 530806, 514 2

Abstract:

A bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.